Acute myeloid leukaemia: guideline history
4 dated versions from 2017 to 2025 listing 8 changes. Pick two versions to see what changed between them; the timeline below shows every version with the event it is anchored to.
- AddedNewly diagnosed, fit, FLT3-ITDQuizartinib with 7+3 as an alternative to midostaurin for FLT3-ITD (not TKD) disease.
- AddedRelapsed or refractory, KMT2A-rearrangedRevumenib, the first menin inhibitor, for relapsed or refractory KMT2A-rearranged acute leukaemia.
- AddedRelapsed or refractory, NPM1-mutatedZiftomenib for NPM1-mutated relapsed or refractory AML.
Timeline
Anchored to: FDA approvals of midostaurin (April 2017, RATIFY), CPX-351 (August 2017), enasidenib (August 2017) and the re-approval of gemtuzumab ozogamicin (September 2017, ALFA-0701)
- addedNewly diagnosed, fit, FLT3-mutated: Midostaurin added to 7+3 induction and consolidation.
- addedNewly diagnosed, therapy-related or secondary AML: CPX-351 (liposomal daunorubicin-cytarabine) in place of 7+3.
- addedNewly diagnosed, favourable-risk, CD33-positive: Gemtuzumab ozogamicin with induction chemotherapy.
Anchored to: Annals of Oncology publication, 2020
- addedNewly diagnosed, unfit for intensive chemotherapy: Venetoclax with azacitidine or low-dose cytarabine recommended over hypomethylating agent alone [I, A].
- addedRelapsed or refractory, FLT3-mutated: Gilteritinib recommended over salvage chemotherapy [I, A].
Anchored to: FDA approval of quizartinib with induction and consolidation for FLT3-ITD AML, July 2023 (QuANTUM-First)
- addedNewly diagnosed, fit, FLT3-ITD: Quizartinib with 7+3 as an alternative to midostaurin for FLT3-ITD (not TKD) disease.
Anchored to: FDA approvals of revumenib for KMT2A-rearranged acute leukaemia (November 2024, AUGMENT-101) and ziftomenib for NPM1-mutated AML (2025, KOMET-001)
- addedRelapsed or refractory, KMT2A-rearranged: Revumenib, the first menin inhibitor, for relapsed or refractory KMT2A-rearranged acute leukaemia.
- addedRelapsed or refractory, NPM1-mutated: Ziftomenib for NPM1-mutated relapsed or refractory AML.
Other cancers
Each entry is anchored to a dated public event and links to the guideline body’s page for the disease; NCCN “Summary of changes” pages sit behind a free login and are not reproduced. Version labels say “update” where the NCCN version number has not been verified. Corrections are welcome via the repository.